Tenax Therapeutics, Inc.
NCM: TENXLive Quote
📈 ZcoreAI Score
Our AI model analyzes Tenax Therapeutics, Inc.'s price action across multiple timeframes using regression channels and statistical scoring.
Get TENX Z-Score →About Tenax Therapeutics, Inc.
Healthcare
Biotechnology
Tenax Therapeutics, Inc., a development-stage pharmaceutical company, develops novel cardiopulmonary therapies in the United States. It develops TNX-101, TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension in heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. Tenax Therapeutics, Inc. was founded in 1967 and is headquartered in Chapel Hill, North Carolina.
📊 Fundamental Analysis
Tenax Therapeutics, Inc. demonstrates a profit margin of 0.0%, which is below the sector average, suggesting competitive pressure.
Return on Equity (ROE) is -55.6%, which indicates that capital utilization is currently under pressure.
At a current price of $14.43, TENX currently sits at the 71st percentile of its 52-week range (Range: $4.63 - $18.38).
🏥 Financial Health
🔴
Profit Margin
Weak
🔴
Return on Equity
Weak
⚠️
Beta (Risk)
Moderate Volatility
Key Financials
Market Cap
$248.08M
Trailing P/E
--
Forward P/E
-9.87
Beta (5Y)
1.19
52W High
$18.38
52W Low
$4.63
Avg Volume
361K
Day High
Day Low